Anti ox40 clone ox 86

Manufactured by BioXCell

Anti-OX40 (clone OX-86) is a monoclonal antibody that recognizes the OX40 receptor. OX40 is a costimulatory molecule expressed on activated T cells. The antibody can be used in research applications to study the role of the OX40 receptor in immune cell function.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd8 clone 2, by BioXCell (2 mentions) Anti gr1 clone rb6 8c5, by BioXCell (1 mentions) Anti pd 1 clone rmp1 14, by BioXCell (1 mentions) Anti ctla 4 clone 9h10, by BioXCell (1 mentions) Gemcitabine, by Selleck Chemicals (1 mentions) Anti tim 3 clone rmt3 23, by BioXCell (1 mentions) Anti lag 3 clone c9b7w, by BioXCell (1 mentions) Streptavidin af647, by Thermo Fisher Scientific (1 mentions) Vectashield antifade mounting medium with dapi, by Vector Laboratories (1 mentions) Anti nk1.1 clone pk136, by BioXCell (1 mentions) Anti cd4 clone gk1, by BioXCell (1 mentions)

4 protocols using anti ox40 clone ox 86

Pharmacological Inhibition in Cancer Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

For in vivo pharmacological inhibition, gemcitabine (Selleck Chemicals) was dosed at 100mg/kg IP. SX-682 (Syntrix Pharmaceuticals) was dosed PO ad libitum (formulated concentration 714mg/kg feed); therapeutic plasma levels (range 0.5–10 μg/mL) were confirmed with this feed using LC/MS-MS. For ICT and Gr1/CD8-neutralizing antibody treatment, anti-PD1 (clone RMP1–14, BioXCell, BE0146), anti-CTLA4 (clone 9H10, BioXCell, BE0131), anti-TIM3 (clone RMT3–23, BioXCell, BE0115), anti-OX40 (clone OX-86, BioXCell, BE0031), anti-41BB (clone LOB12.3, BioXCell, BE0169), anti-LAG3 (clone C9B7W, BioXCell, BE0174), anti-CD8 (clone 2.43, BioXCell, BE0061) and anti-Gr1 (clone RB6–8C5, BioXCell, BE0075), antibodies (or their respective isotype IgG controls) were intraperitoneally administered at 200μg per injection three times per week. The duration of treatment was 4 weeks before endpoint analysis and survival analysis unless otherwise indicated.

Gulhati P., Schalck A., Jiang S., Shang X., Wu C.J., Hou P., Ruiz S.H., Soto L.S., Parra E., Ying H., Han J., Dey P., Li J., Deng P., Sei E., Maeda D.Y., Zebala J.A., Spring D.J., Kim M., Wang H., Maitra A., Moore D., Clise-Dwyer K., Wang Y.A., Navin N.E, & DePinho R.A. (2022). Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/2 results in anti-tumor immunity and durable response in pancreatic cancer. Nature cancer, 4(1), 62-80.

+ Open protocol

+ Expand

Analysis of OX40 Expression in Transplanted Tissues

Check if the same lab product or an alternative is used in the 5 most similar protocols

Intestinal tissues were harvested from transplanted mice (day 7 post-transplant) and frozen in Optimal Cutting Temperature (OCT) embedding compound and stored at −80°C until further use. Tissue sections were cut longitudinally into 10 μm thick sections using a cryostat. Immunofluorescence staining was carried out using standard procedures using the following primary antibodies: anti-OX40 (clone OX86, BioXcell) and CD90.1-Biotin (Invitrogen). OX40 expression was detected using donkey anti-rat IgG-AF488 (Abcam) and Streptavidin-AF647 (Invitrogen) respectively. The sections were finally mounted with VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratories) and imaged with Nikon A1R-Si-MP multiphoton confocal microscope using a Nikon CF160 Plan Apo Lambda 10x/0.45 numerical aperture objective lens.

Alam I.S., Simonetta F., Scheller L., Mayer A.T., Murty S., Vermesh O., Nobashi T.W., Lohmeyer J.K., Hirai T., Baker J., Lau K.H., Negrin R, & Gambhir S.S. (2020). Visualization of activated T cells by OX40-immunoPET as a strategy for diagnosis of acute Graft-versus-Host-Disease. Cancer research, 80(21), 4780-4790.

+ Open protocol

+ Expand

Immune checkpoint inhibitor protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Therapeutic anti-OX40 (Clone OX-86; Catalog#:BE0031), anti-PD-1 (Clone RMT3-23; Catalog#BE0115), anti-CD4 (Clone GK1.5; Catalog#:BE0003-1), anti-CD8 (Clone 2.43; Catalog#:BE0061), anti-NK1.1 (Clone PK136; Catalog#:BE0036) and control rat IgG2a mAb (Clone 2A3; Catalog#:BE0089) were purchased from BioXcell (West Lebanon, NH). Antibodies used for flow cytometry were purchased from Tianjing Sungene (Tianjing, China) and eBioscience (San Diego, CA).

Guo Z., Wang X., Cheng D., Xia Z., Luan M, & Zhang S. (2014). PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer. PLoS ONE, 9(2), e89350.

+ Open protocol

+ Expand

Combination Immunotherapy for Tumor Eradication

Check if the same lab product or an alternative is used in the 5 most similar protocols

Treatment started on day 4 after i.p. inoculation of 7 × 10⁴ CT26.Fluc cells or 10⁵ cells of MyC-CaP.Fluc in 500 μL of Opti-MEM. For treatments, mice were randomized and SV (10⁷ transduction units [TU]/mL), in a total volume of 500 μL, was injected i.p. into the left side of the animal once for CT26.Fluc and 4 days a week (days 1, 2, 3, and 4) for a total of 4 weeks for MyC-CaP.Fluc-inoculated mice. The immune checkpoint inhibitor anti-OX40 (clone OX-86, Bio X Cell) was injected i.p. into the left side of the animal at a dose of 250 μg per injection (once per week for the CT26.Fluc and three times per week for the MyC-CaP.Fluc tumor-bearing mice). Therapeutic efficacy of the treatment was monitored in two ways: tumor luminescence and survival. Noninvasive bioluminescent imaging was performed using the IVIS (in vivo imaging system) Spectrum imaging system (Caliper Life Sciences) at the indicated time points, and tumor growth was quantified using the Living Image 3.0 software (Caliper Life Sciences) as previously described.⁸⁶ (link) Relative tumor growth for each mouse was calculated by dividing total body counts of a given day by total body counts of the first IVIS image. Survival was monitored and recorded daily.

Scherwitzl I., Opp S., Hurtado A.M., Pampeno C., Loomis C., Kannan K., Yu M, & Meruelo D. (2020). Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors. Molecular Therapy Oncolytics, 17, 431-447.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!